PAOG Cannabis Pharmaceutical and Nutraceutical 2021 Strategy Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2020
Sandusky, Ohio--(Newsfile Corp. - January 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2020.
In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
The global asthma and COPD market is expected to reach $50 billion by 2022.
PAOG recently announced a key contract with a Contract Research Organization (CRO) to advance the company's RespRx formula through the process to becoming an approved pharmaceutical treatment.
The company also recently confirmed that the company expects to realize and report in Q4 2020 the first revenue from assets acquired in the course of 2020.
Look for the update this Thursday to learn more.